{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T16:21:00Z","timestamp":1715962860639},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,11]]},"DOI":"10.7759\/cureus.10392","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T20:47:55Z","timestamp":1599857275000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case Report of Atypical Hemolytic Uremic Syndrome in a Two-Month-Old Infant With a Negative Reported Genetic Profile and Five-Year Follow-Up on Eculizumab"],"prefix":"10.7759","author":[{"given":"Siddharth","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laith","family":"Sweis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0929-693x(01)80196-2","article-title":"Syndrome h\u00e9molytique et ur\u00e9mique typique post-diarrh\u00e9e: aspects cliniques [Post-diarrhea hemolytic-uremic syndrome: clinical aspects]","volume":"8","author":"Loirat C","year":"2001","unstructured":"Loirat C. Syndrome h\u00e9molytique et ur\u00e9mique typique post-diarrh\u00e9e: aspects cliniques [Post-diarrhea hemolytic-uremic syndrome: clinical aspects]. Arch Pediatr. 2001, 8:S776-S784. 10.1016\/s0929-693x(01)80196-2","journal-title":"Arch Pediatr"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-709865","article-title":"HUS and atypical HUS","volume":"129","author":"Jokiranta TS","year":"2017","unstructured":"Jokiranta TS . HUS and atypical HUS. Blood. 2017, 129:2847-2856. 10.1182\/blood-2016-11-709865","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris M","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, et al.. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010, 5:1844-1859. 10.2215\/CJN.02210310","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-1787","article-title":"Eculizumab as first-line therapy for atypical hemolytic uremic syndrome","volume":"133","author":"Christmann M","year":"2014","unstructured":"Christmann M, Hansen M, Bergmann C, et al.. Eculizumab as first-line therapy for atypical hemolytic uremic syndrome. Pediatrics. 2014, 133:e1759. 10.1542\/peds.2013-1787","journal-title":"Pediatrics"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12763","article-title":"Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment","volume":"23","author":"Raina R","year":"2019","unstructured":"Raina R, Krishnappa V, Blaha T, et al.. Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019, 23:4-21. 10.1111\/1744-9987.12763","journal-title":"Ther Apher Dial"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi V","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al.. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013, 8:554-562. 10.2215\/CJN.04760512","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-008-0964-1","article-title":"Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome","volume":"24","author":"Ariceta G","year":"2009","unstructured":"Ariceta G, Besbas N, Johnson S, et al.. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009, 24:687-696. 10.1007\/s00467-008-0964-1","journal-title":"Pediatr Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000188221","article-title":"Outcome and prognostic determinants in the hemolytic uremic syndrome of children","volume":"68","author":"T\u00f6nshoff B","year":"1994","unstructured":"T\u00f6nshoff B, Sammet A, Sanden I, et al.. Outcome and prognostic determinants in the hemolytic uremic syndrome of children. Nephron. 1994, 68:63-70. 10.1159\/000188221","journal-title":"Nephron"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-014-0416-x","article-title":"Hemolytic uremic syndrome","volume":"36","author":"Mele C","year":"2014","unstructured":"Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol. 2014, 36:399-420. 10.1007\/s00281-014-0416-x","journal-title":"Semin Immunopathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003573","article-title":"A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)","volume":"3","author":"Rathbone J","year":"2013","unstructured":"Rathbone J, Kaltenthaler E, Richards A, Tappenden P, Bessey A, Cantrell A. A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS). BMJ Open. 2013, 3:e003573. 10.1136\/bmjopen-2013-003573","journal-title":"BMJ Open"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum LA","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, et al.. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int. 2016, 89:701-711. 10.1016\/j.kint.2015.11.026","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2016.31.10.1516","article-title":"Clinical practice guidelines for the management of atypical hemolytic uremic syndrome in Korea","volume":"31","author":"Cheong HI","year":"2016","unstructured":"Cheong HI, Jo SK, Yoon SS, et al.. Clinical practice guidelines for the management of atypical hemolytic uremic syndrome in Korea. J Korean Med Sci. 2016, 31:1516-1528. 10.3346\/jkms.2016.31.10.1516","journal-title":"J Korean Med Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-016-0288-3","article-title":"Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment","volume":"30","author":"Walle JV","year":"2017","unstructured":"Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol. 2017, 30:127-134. 10.1007\/s40620-016-0288-3","journal-title":"J Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy066","article-title":"Atypical hemolytic uremic syndrome: a syndrome in need of clarity","volume":"12","author":"Berger BE","year":"2018","unstructured":"Berger BE. Atypical hemolytic uremic syndrome: a syndrome in need of clarity. Clin Kidney J. 2018, 12:338-347. 10.1093\/ckj\/sfy066","journal-title":"Clin Kidney J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2014.00097","article-title":"Extra-renal manifestations of complement-mediated thrombotic microangiopathies","volume":"2","author":"Hofer J","year":"2014","unstructured":"Hofer J, Rosales A, Fischer C, Giner T. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front Pediatr. 2014, 2:97. 10.3389\/fped.2014.00097","journal-title":"Front Pediatr"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-012-2276-8","article-title":"Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome","volume":"27","author":"Vilalta R","year":"2012","unstructured":"Vilalta R, Lara E, Madrid A, et al.. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol. 2012, 27:2323-2326. 10.1007\/s00467-012-2276-8","journal-title":"Pediatr Nephrol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2016.05.009","article-title":"Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab","volume":"435","author":"Riedl M","year":"2016","unstructured":"Riedl M, Hofer J, Giner T, et al.. Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab. J Immunol Methods. 2016, 435:60-67. 10.1016\/j.jim.2016.05.009","journal-title":"J Immunol Methods"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat C","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, et al.. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016, 31:15-39. 10.1007\/s00467-015-3076-8","journal-title":"Pediatr Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-017-3813-2","article-title":"Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update","volume":"33","author":"Ardissino G","year":"2018","unstructured":"Ardissino G, Tel F, Sgarbanti M, et al.. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update. Pediatr Nephrol. 2018, 33:457-461. 10.1007\/s00467-017-3813-2","journal-title":"Pediatr Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1159\/000492033","article-title":"When to stop eculizumab in complement-mediated thrombotic microangiopathies","volume":"48","author":"Olson SR","year":"2018","unstructured":"Olson SR, Lu E, Sulpizio E, Shatzel JJ, Rueda JF, DeLoughery TG. When to stop eculizumab in complement-mediated thrombotic microangiopathies. Am J Nephrol. 2018, 48:96-107. 10.1159\/000492033","journal-title":"Am J Nephrol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/40430-a-case-report-of-atypical-hemolytic-uremic-syndrome-in-a-two-month-old-infant-with-a-negative-reported-genetic-profile-and-five-year-follow-up-on-eculizumab","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:22:44Z","timestamp":1707506564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/40430-a-case-report-of-atypical-hemolytic-uremic-syndrome-in-a-two-month-old-infant-with-a-negative-reported-genetic-profile-and-five-year-follow-up-on-eculizumab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.10392","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,11]]}}}